Patents by Inventor Ernest S. Kawasaki

Ernest S. Kawasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding N?2 CSF-1 (short form) and carboxy truncated fragment thereof
    Patent number: 6204020
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both “long” and “short” forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: March 20, 2001
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments thereof
    Patent number: 6156300
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 5, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding NV2 (long form) and carboxy truncated fragments thereof
    Patent number: 6146851
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: November 14, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof
    Patent number: 6117422
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 12, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof
    Patent number: 6103224
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 15, 2000
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle N. Van Arsdell, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Detection of carcinoma metastases by nucleic acid amplification
    Patent number: 5766888
    Abstract: Methods are provided for detecting carcinoma metastases in selected body tissues and fluids. These methods offer greater than 1,000-fold enhanced sensitivity compared to prior standard diagnostic methods. In one embodiment of the invention, target carcinoma associated nucleic acid sequences are identified for detecting minimal residual disease in lung carcinomas. The methods utilize nucleic acid amplification techniques, preferably, the polymerase chain reaction.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 16, 1998
    Assignees: Roche Molecular Systems, Inc., The University of California
    Inventors: Robert E. Sobol, Mark R. Green, Ernest S. Kawasaki
  • DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
    Patent number: 5681719
    Abstract: DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: October 28, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N- 3 deletion mutants of the long form of CSF-1
    Patent number: 5672343
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 30, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Yee Coyne, Robert F. Halenbeck, Kirston E. Koths
  • N-.gradient.3 deletion mutants of the short form of CSF-1
    Patent number: 5643563
    Abstract: New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: July 1, 1997
    Assignee: Chiron Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • DNA encoding various forms of colony stimulating factor-1
    Patent number: 5573930
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: November 12, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Detection of carcinoma metastases by nucleic acid amplification
    Patent number: 5543296
    Abstract: Methods are provided for detecting carcinoma metastases in selected body tissues and fluids. These methods offer greater than 1,000-fold enhanced sensitivity compared to prior standard diagnostic methods. In one embodiment of the invention, target carcinoma associated nucleic acid sequences are identified for detecting minimal residual disease in lung carcinomas. The methods utilize nucleic acid amplification techniques, preferably, the polymerase chain reaction.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: August 6, 1996
    Assignees: Hoffman-La Roche Inc., Regents of the University of California
    Inventors: Robert E. Sobol, Mark R. Green, Ernest S. Kawasaki
  • Recombinant colony stimulating factor-1
    Patent number: 5470569
    Abstract: A colony stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: November 28, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Ernest S. Kawasaki, Martha B. Ladner, Janelle N. Van Arsdell, Alice M. Wang, Peter Ralph, Mazie Y. Coyne, Mary K. Warren
  • Chimeric messenger RNA detection methods
    Patent number: 5057410
    Abstract: The invention provides highly sensitive methods for detecting specific sequences contained in chimeric mRNA. The mRNA sequences are reverse transcribed into complementary DNA (cDNA), amplified by the Polymerase Chain Reaction, and detected by hybridization with a labeled sequence specific oligonucleotide probe. The method is particularly valuable for the detection of chimeric mRNAs experessed by activated oncogenes that result from aberrant genetic rearragements such as chromosomal translocations.
    Type: Grant
    Filed: August 5, 1988
    Date of Patent: October 15, 1991
    Assignee: Cetus Corporation
    Inventors: Ernest S. Kawasaki, Francis P. McCormick, Owen O. Witto
  • Human IL-2 like polypeptides, DNA sequences and recombinant DNA molecules therefore and methods for the production and use thereof
    Patent number: 4939093
    Abstract: DNA sequences and recombinant DNA molecules which encode human IL-2 IL-2 like polypeptides, hosts transformed with vectors carrying the DNA sequences as inserts, methods for their production and therapeutic formulations utilizing the IL-2 and IL-2 like polypeptides are provided.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: July 3, 1990
    Assignee: Cetus Corporation
    Inventors: Michael P. McGrogan, Ernest S. Kawasaki, Michael V. Doyle, David F. Mark